Harrow, Inc. engages in the development, production, and sale of innovative medications. The company is headquartered in Nashville, Tennessee and currently employs 382 full-time employees. The company went IPO on 2013-02-08. The firm offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. The company owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. The company owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. The company owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
How did HROW's recent EPS compare to expectations?
The most recent EPS for Harrow Inc is $-0.63, beating expectations of $-0.4.
How did Harrow Inc HROW's revenue perform in the last quarter?
Harrow Inc revenue for the last quarter is $-0.63
What is the revenue estimate for Harrow Inc?
According to 10 of Wall street analyst, the revenue estimate of Harrow Inc range from $89.04M to $66.99M
What's the earning quality score for Harrow Inc?
Harrow Inc has a earning quality score of B+/57.305946. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Harrow Inc report earnings?
Harrow Inc next earnings report is expected in 2026-08-09
What are Harrow Inc's expected earnings?
Harrow Inc expected earnings is $53.46M, according to wall-street analysts.
Did Harrow Inc beat earnings expectations?
Harrow Inc recent earnings of $44.2M does not beat expectations.
